Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma

Trial Profile

Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Ofatumumab (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 21 Jul 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-001597-29).
    • 21 Jul 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
    • 26 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top